Replies to post #5636 on Cytodyn Inc (CYDY)

[buckysherm]

Two words : up list. Forced short covering and the beginning of institutional buyers.

[Inoviorulez]

It needs an uplist to the NASDAQ IMO. Considering that it is in two phase 3 trials It should uplist. Most other small cap biotechs uplist with only phase 2 trials in process. I don't predict it will move much if they don't uplist. Either that or results of phase 3 come out. But phase 3 results for the adjunct therapy should take until July 2017 to September 2017 IMO. So at least one year, because they added the 100 patients for placebo control.